Peptinnovate has been funded by visionary investors, who have enabled it to de-risk the lead molecule PIN201104 through preclinical work, and deliver a truly transformative treatment for immuno-inflammatory disorders for clinical studies. PIN201104 will be the first Immune Regulating Asthma Drug (IMRAD).

For more information please contact Richard Nagle, Chief Executive Officer  on +44 (0)1438 906978 or email